---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-099354"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:14:19.579681+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for CER-1236 Phase 1 trial in AML; start expected Q1 2025

## Summary
- FDA cleared CERo's IND for Phase 1 trial of CER-1236 in acute myelogenous leukemia (AML).
- Interim CEO Chris Ehrlich said first in-human trial expected to begin Q1 2025.
- CER-1236 uses the Chimeric Engulfment Receptor T cell (CER-T) platform targeting hematologic malignancies.
- CERo believes CER-T cells may offer broader application than CAR-T, including solid tumors.
- Company to deploy resources expeditiously; shares recent program update as key milestone.

## SEC filing metadata
- accession: 0001213900-24-099354
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024099354/0001213900-24-099354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024099354/ea0221421-8k_cerothera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-099354
- JSON: https://secwatch.observer/filing/0001213900-24-099354.json
- Plain text: https://secwatch.observer/filing/0001213900-24-099354.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.